Technical Analysis for GOSS - Gossamer Bio, Inc.

Grade Last Price % Change Price Change
grade D 16.46 2.11% 0.34
GOSS closed down 1.89 percent on Thursday, October 17, 2019, on 72 percent of normal volume.
1 Watcher
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong N/A Down Up
See historical GOSS trend table...

Date Alert Name Type % Chg
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 2.11%
MACD Bullish Signal Line Cross Bullish 2.11%
Wide Bands Range Expansion 2.11%
Slingshot Bearish Bearish Swing Setup 0.18%
Wide Bands Range Expansion 0.18%
Up 3 Days in a Row Strength 0.18%
Oversold Stochastic Weakness 0.18%
Slingshot Bearish Bearish Swing Setup 2.20%
New 52 Week Low Weakness 2.20%
Outside Day Range Expansion 2.20%

Older signals for GOSS ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Read My Charts!
Configure default chart indicators
GOSS Chart by TradingView
Basic chart:
Profile
Gossamer Bio is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. Its goal is to be an industry leader in each of these therapeutic areas and to enhance and extend the lives of patients suffering from such diseases.
Biopharmaceutical Life Sciences Disease Inflammation Millennium Pharmaceuticals Takeda Pharmaceutical Company
Is GOSS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Oct 11 The Daily Biotech Pulse: Therapix Extends Merger Deadline, Five Prime Restructures, Gilead-Galapagos Rheumatism Drug Readout
Oct 9 The Daily Biotech Pulse: FDA Approves Clinuvel Drug, Aclaris Files Patent Lawsuit Against Taro, Viela Out-Licenses Autoimmune Disorder Drug
Oct 2 The Daily Biotech Pulse: J&J Settles Ohio Opioid Lawsuit, Teligent Explores Options For Certain Assets, Novartis Reports Cosentyx Data
Sep 30 Weekly CEO Buys Highlight
Sep 27 Gossamer Bio up 7% as insiders buy
Sep 25 Gossamer Bio Announces Participation in the 2019 Cantor Global Healthcare Conference
Sep 23 Seth Klarman Further Increases Translate Bio Stake
Sep 16 56 Biggest Movers From Friday
Sep 13  Gossamer Bio Announces the Departure of Dr. Otello Stampacchia from its Board of Directors
Sep 10 Baupost's Seth Klarman Dives Further Into Translate Bio
See more GOSS news...
Indicators
Indicator Value
52 Week High 25.06
52 Week Low 14.63
Average Volume 519,342
200-Day Moving Average 0.0
50-Day Moving Average 18.7375
20-Day Moving Average 16.9283
10-Day Moving Average 15.6535
Average True Range 1.2685
ADX 29.32
+DI 16.3812
-DI 22.3778
Chandelier Exit (Long, 3 ATRs ) 18.8045
Chandelier Exit (Short, 3 ATRs ) 18.4355
Upper Bollinger Band 21.1426
Lower Bollinger Band 12.714
Percent B (%b) 0.4
BandWidth 49.789997
MACD Line -1.0582
MACD Signal Line -1.1176
MACD Histogram 0.0594
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 17.68
Resistance 3 (R3) 17.75 17.29 17.42
Resistance 2 (R2) 17.29 16.90 17.26 17.33
Resistance 1 (R1) 16.71 16.65 16.48 16.64 17.25
Pivot Point 16.25 16.25 16.14 16.22 16.25
Support 1 (S1) 15.67 15.86 15.44 15.60 14.99
Support 2 (S2) 15.21 15.61 15.18 14.91
Support 3 (S3) 14.63 15.21 14.82
Support 4 (S4) 14.56